GlassScriptPhysician profile
Natalie Rose Lukaszewski
NPI 1518275411
$7,563.23
in general payments reported to CMS, 2019-2025
31 companies · $1,590 in 2025
The $1,590 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $859 · 2022: $1,492 · 2023: $1,940 · 2024: $1,683 · 2025: $1,590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,852 · Education: $361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,852.04 |
| Education | $360.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,310.40 | 2021-2025 | Tremfya, Remicade, Simponi Aria |
| Abbvie INC. | $1,256.91 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $537.76 | 2021-2025 | |
| Galderma Laboratories, L.P. | $458.07 | 2021-2025 | Nemluvio, Aklief, Twyneo |
| Genzyme Corporation | $415.86 | 2021-2025 | |
| Pfizer INC. | $399.56 | 2021-2025 | |
| Lilly USA, LLC | $395.35 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $304.39 | 2022-2024 | Sotyktu |
| Medimetriks Pharmaceuticals, INC. | $279.48 | 2022-2025 | Neo-Synalar, Clindacin Etz |
| Amgen INC. | $238.15 | 2023-2025 | Otezla, Enbrel, Otezla |
| Journey Medical Corporation | $237.82 | 2022-2023 | |
| Leo Pharma INC. | $228.78 | 2021-2022 | |
| Incyte Corporation | $216.23 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $186.49 | 2021-2025 | Absorica Ld, Winlevi |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $176.85 | 2021-2025 | Cabtreo, Jublia, Siliq |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $144.88 | 2024-2025 | Bimzelx |
| Allergan, INC. | $125.00 | 2022 | |
| Arcutis Biotherapeutics, INC. | $81.55 | 2023-2024 | Zoryve |
| Organon LLC | $74.41 | 2025 | Vtama |
| Dermavant Sciences, INC. | $71.79 | 2023-2024 | Vtama |
| Vyne Pharmaceuticals INC. | $67.40 | 2021 | |
| Botanix Sb INC | $65.56 | 2025 | Sofdra |
| Regeneron Healthcare Solutions, INC. | $57.44 | 2024 | Dupixent |
| Epi Health, LLC | $49.12 | 2021-2022 | |
| Biofrontera INC. | $42.54 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Solta Medical, A Division of Bausch Health US, LLC | $37.83 | 2025 | Fraxel |
| Almirall LLC | $32.29 | 2021-2024 | Klisyri |
| Mission Pharmacal Company | $23.79 | 2022 | |
| Kyowa Kirin, INC. | $20.27 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.50 | 2021 | |
| Verrica Pharmaceuticals INC. | $12.76 | 2023 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Lukaszewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.